Your browser doesn't support javascript.
loading
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin, Kevin H; Rutter, Justine C; Xie, Abigail; Killarney, Shane T; Vaganay, Camille; Benaksas, Chaima; Ling, Frank; Sodaro, Gaetano; Meslin, Paul-Arthur; Bassil, Christopher F; Fenouille, Nina; Hoj, Jacob; Washart, Rachel; Ang, Hazel X; Cerda-Smith, Christian; Chaintreuil, Paul; Jacquel, Arnaud; Auberger, Patrick; Forget, Antoine; Itzykson, Raphael; Lu, Min; Lin, Jiaxing; Pierobon, Mariaelena; Sheng, Zhecheng; Li, Xinghai; Chilkoti, Ashutosh; Owzar, Kouros; Rizzieri, David A; Pardee, Timothy S; Benajiba, Lina; Petricoin, Emanuel; Puissant, Alexandre; Wood, Kris C.
Afiliación
  • Lin KH; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Rutter JC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Xie A; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Killarney ST; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Vaganay C; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Benaksas C; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Ling F; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Sodaro G; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Meslin PA; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Bassil CF; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Fenouille N; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Hoj J; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Washart R; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Ang HX; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Cerda-Smith C; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Chaintreuil P; Université Côte d'Azur, Nice, France.
  • Jacquel A; Université Côte d'Azur, Nice, France.
  • Auberger P; Université Côte d'Azur, Nice, France.
  • Forget A; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Itzykson R; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Lu M; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Lin J; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
  • Pierobon M; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA.
  • Sheng Z; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
  • Li X; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Chilkoti A; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Owzar K; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
  • Rizzieri DA; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Pardee TS; Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA.
  • Benajiba L; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
  • Petricoin E; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA.
  • Puissant A; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France. alexandre.puissant@inserm.fr.
  • Wood KC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA. kris.wood@duke.edu.
Nat Cancer ; 3(7): 837-851, 2022 07.
Article en En | MEDLINE | ID: mdl-35668193
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Proteínas Proto-Oncogénicas c-akt Tipo de estudio: Prognostic_studies Límite: Animals País/Región como asunto: America do norte Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Proteínas Proto-Oncogénicas c-akt Tipo de estudio: Prognostic_studies Límite: Animals País/Región como asunto: America do norte Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido